Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities - Furlong, T; Storb, R; Anasetti, C (Bone Marrow Transplant, 2000)
et al.